MATTHEW COTTON: Open Payments
NPI 1376914101 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 49 payments from 13 companies in 2025. Trend: 2023 $258 · 2024 $156 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $235 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $183 |
| ABBVIE INC. | 11 | $177 |
| Lilly USA, LLC | 7 | $124 |
| Medtronic, Inc. | 1 | $110 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Antares Pharma, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
Products named: CAPLYTA, MOUNJARO, Wegovy, VRAYLAR, SYMPLICITY G3, Ozempic, Rybelsus, QULIPTA.
Industry payments across TX — which companies pay providers there.
